Orforglipron vs Tirzepatide
Side-by-side comparison of Orforglipron and Tirzepatide: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
Orforglipron
Tirzepatide
Orforglipron
Orforglipron (also known as LY3502970) is Eli Lilly's oral, non-peptide, small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, approved in the US for weight management and submitted to the FDA for type 2…
Lowest listed price: $249.99 across 1 listing
Full Orforglipron profileTirzepatide
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2. It is a 39-amino-acid…
Lowest listed price: $49.00 across 14 listings
Full Tirzepatide profileSide-by-side comparison
| Attribute | Orforglipron | Tirzepatide |
|---|---|---|
| Category | Weight Loss | Metabolic & Weight Loss |
| Research Stage | FDA Approved | FDA Approved |
| Mechanism of Action | Orforglipron (LY3502970; OWL833) is an oral, non-peptide (small-molecule) GLP-1 receptor agonist. It engages the GLP-1 receptor (GLP1R) through a binding mode fundamentally different from native GLP-1 or peptide-based analogs. Non-Peptide Binding at a Distinct… | Dual GLP-1 and GIP Receptor Agonism Tirzepatide simultaneously activates two incretin receptors: the GLP-1 receptor and the GIP receptor. While the GLP-1 receptor component provides the well-established effects of GLP-1 agonism (glucose-dependent insulin… |
| Half-Life | ~29-49 hours (supports once-daily oral dosing) | ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification |
| Typical Dose Range | — | 2500 mcg (2.5 mg) starting dose, titrated every 4 weeks through 5000, 7500, 10000, 12500, to 15000 mcg (15 mg) maximum weekly dose |
| Dosing Frequency | Once daily | Once weekly subcutaneous injection |
| Administration | — | Subcutaneous (weekly) |
| Side Effects | Orforglipron's side effect profile closely mirrors the GLP-1 receptor agonist class as a whole, dominated by gastrointestinal effects that typically improve with continued dosing and proper titration. Common Gastrointestinal Effects (incidence 20-50% depending… | Mild to moderate nausea (especially at initiation), headache, fatigue, constipation or diarrhea, abdominal distension. Injection site reactions. Rare: hypoglycemia, increased heart rate, pancreatitis. |
| Molecular Weight | 882.97 g/mol | 4813.5 Da |
| Common Vial Sizes | — | 5mg, 10mg, 15mg |
Price tracking
Price History
3 data points- BM
- Half Nattys
- Ion Peptide
Orforglipron: potential benefits
- No structured benefit list published.
Tirzepatide: potential benefits
- Mean body weight reduction of 22.5% at 72 weeks - highest of any anti-obesity medication (PMID: 35658024)
- 36.2% of participants achieved greater than or equal to 25% body weight loss (PMID: 35658024)
- Significant HbA1c reduction in type 2 diabetes (up to 2.4% at 40 weeks in the SURPASS-5 add-on-to-insulin trial) (PMID: 35133415)
- Potentially superior lean mass preservation versus GLP-1-only agents due to GIP component
- Dual incretin mechanism providing complementary metabolic benefits
- Improved lipid profiles including triglycerides, LDL cholesterol, and HDL cholesterol
- Reduction in waist circumference and markers of visceral adiposity (PMID: 37840095)
Frequently asked
What's the difference between Orforglipron and Tirzepatide?
Orforglipron is a weight loss that orforglipron (ly3502970; owl833) is an oral, non-peptide (small-molecule) glp-1 receptor agonist. it engages the glp-1 receptor (glp1r) through a binding mode fundamentally…. Tirzepatide is a metabolic & weight loss that dual glp-1 and gip receptor agonism tirzepatide simultaneously activates two incretin receptors: the glp-1 receptor and the gip receptor. while the glp-1 receptor component…. The two differ in mechanism, half-life (~29-49 hours (supports once-daily oral dosing) vs ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification), and typical dose range.
Which has the longer half-life, Orforglipron or Tirzepatide?
Orforglipron has a half-life of ~29-49 hours (supports once-daily oral dosing). Tirzepatide has a half-life of ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, Orforglipron or Tirzepatide?
Lowest listed price on BodyHackGuide: Orforglipron from $249.99, Tirzepatide from $49.00. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack Orforglipron and Tirzepatide?
Stacking depends on mechanism overlap, safety profile, and goals. Orforglipron and Tirzepatide should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy Orforglipron or Tirzepatide
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.